JP2019520361A5 - - Google Patents

Download PDF

Info

Publication number
JP2019520361A5
JP2019520361A5 JP2018567665A JP2018567665A JP2019520361A5 JP 2019520361 A5 JP2019520361 A5 JP 2019520361A5 JP 2018567665 A JP2018567665 A JP 2018567665A JP 2018567665 A JP2018567665 A JP 2018567665A JP 2019520361 A5 JP2019520361 A5 JP 2019520361A5
Authority
JP
Japan
Prior art keywords
formulation
intranasal
naltrexone
intravail
dodecyl maltoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018567665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520361A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/039300 external-priority patent/WO2017223566A1/en
Publication of JP2019520361A publication Critical patent/JP2019520361A/ja
Publication of JP2019520361A5 publication Critical patent/JP2019520361A5/ja
Priority to JP2022058125A priority Critical patent/JP7492548B2/ja
Pending legal-status Critical Current

Links

JP2018567665A 2016-06-24 2017-06-26 アルコール使用障害の処置のための組成物、装置、及び、方法 Pending JP2019520361A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022058125A JP7492548B2 (ja) 2016-06-24 2022-03-31 アルコール使用障害の処置のための組成物、装置、及び、方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662354465P 2016-06-24 2016-06-24
US62/354,465 2016-06-24
US201662419736P 2016-11-09 2016-11-09
US62/419,736 2016-11-09
PCT/US2017/039300 WO2017223566A1 (en) 2016-06-24 2017-06-26 Compositions, devices, and methods for the treatment of alcohol use disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022058125A Division JP7492548B2 (ja) 2016-06-24 2022-03-31 アルコール使用障害の処置のための組成物、装置、及び、方法

Publications (2)

Publication Number Publication Date
JP2019520361A JP2019520361A (ja) 2019-07-18
JP2019520361A5 true JP2019520361A5 (cg-RX-API-DMAC7.html) 2020-07-27

Family

ID=60784803

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018567665A Pending JP2019520361A (ja) 2016-06-24 2017-06-26 アルコール使用障害の処置のための組成物、装置、及び、方法
JP2022058125A Active JP7492548B2 (ja) 2016-06-24 2022-03-31 アルコール使用障害の処置のための組成物、装置、及び、方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022058125A Active JP7492548B2 (ja) 2016-06-24 2022-03-31 アルコール使用障害の処置のための組成物、装置、及び、方法

Country Status (13)

Country Link
US (1) US20190209464A1 (cg-RX-API-DMAC7.html)
EP (1) EP3474842A4 (cg-RX-API-DMAC7.html)
JP (2) JP2019520361A (cg-RX-API-DMAC7.html)
KR (2) KR102634829B1 (cg-RX-API-DMAC7.html)
CN (1) CN109789122A (cg-RX-API-DMAC7.html)
AU (2) AU2017281941A1 (cg-RX-API-DMAC7.html)
CA (1) CA3028731A1 (cg-RX-API-DMAC7.html)
MX (2) MX2018015985A (cg-RX-API-DMAC7.html)
NZ (1) NZ750067A (cg-RX-API-DMAC7.html)
PH (1) PH12018502738A1 (cg-RX-API-DMAC7.html)
RU (2) RU2022103366A (cg-RX-API-DMAC7.html)
SG (2) SG10202013034QA (cg-RX-API-DMAC7.html)
WO (1) WO2017223566A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ750067A (en) * 2016-06-24 2025-11-28 Aegis Therapeutics Llc Compositions, devices, and methods for the treatment of alcohol use disorder
US11069446B1 (en) * 2016-09-28 2021-07-20 Cerner Innovation, Inc. Predicting addiction relapse and decision support tool
CA3043028A1 (en) * 2016-11-09 2018-05-17 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
WO2018093666A1 (en) * 2016-11-18 2018-05-24 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス,エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
US20210220346A1 (en) * 2018-05-17 2021-07-22 Aegis Therapeutics Llc Formulations and methods for the prevention of opioid overdose
WO2020132263A1 (en) * 2018-12-20 2020-06-25 Aegis Therapeutics, Inc. Compositions, devices, and methods for the treatment of overdose and reward-based disorders
CA3134943A1 (en) 2019-03-26 2020-10-01 Pocket Naloxone Corp. Devices and methods for delivering pharmaceutical compositions
JP7900916B2 (ja) * 2019-05-16 2026-08-05 株式会社新日本科学 経鼻投与用の粉末製剤及びその製造方法
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
CA3166250A1 (en) 2020-02-05 2021-08-12 Gregory G. Plucinski Drug products for intranasal administration and uses thereof
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
CA3227828A1 (en) 2021-08-04 2023-02-09 Indivior Inc. Compositions and methods for the treatment of opioid overdose
EP4469027A4 (en) * 2022-01-26 2025-11-12 Tulex Pharmaceuticals Inc NEW COMPOSITIONS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US5069895A (en) * 1989-11-09 1991-12-03 Diamond Ivan F Methods for the treatment of alcohol intoxication and dependence
EP0444778A1 (en) * 1990-02-14 1991-09-04 Alcon Laboratories, Inc. Use of alkyl saccharides to enhance the penetration of drugs
EP1423116A1 (en) * 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US9895444B2 (en) * 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
WO2008095086A2 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
JP2010537990A (ja) * 2007-08-27 2010-12-09 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール中毒および薬物嗜癖の処置のための医薬の組み合わせ
WO2009128474A1 (ja) * 2008-04-16 2009-10-22 財団法人化学及血清療法研究所 トロンビン固定化生体吸収性シート製剤の製造方法
ES2686299T3 (es) * 2010-10-29 2018-10-17 Troikaa Pharmaceuticals Ltd Composiciones nasales de vitamina B12
HRP20180233T1 (hr) * 2011-05-13 2018-06-01 Euro-Celtique S.A. Intranazalni farmaceutski oblici doziranja koji sadrže nalokson
US10485798B2 (en) * 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
US20140171458A1 (en) * 2012-12-13 2014-06-19 3B Pharmaceuticals, Inc. Intranasal naltrexone
DE202013105715U1 (de) * 2013-08-22 2014-02-19 Sipnose Ltd. Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers
WO2015095389A1 (en) 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
US9480644B2 (en) * 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
NZ750067A (en) 2016-06-24 2025-11-28 Aegis Therapeutics Llc Compositions, devices, and methods for the treatment of alcohol use disorder

Similar Documents

Publication Publication Date Title
RU2019101810A (ru) Составы, устройства и способы для лечения алкогольной зависимости
JP2023133494A (ja) ステロイドの抗痙攣活性
JP2022088592A5 (cg-RX-API-DMAC7.html)
JP4500045B2 (ja) 感冒の治療のための組成物
JP2505944B2 (ja) (S)―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
US9844580B2 (en) Recombinant human CC10 and compositions thereof for use in the treatment of nasal rhinitis
CN102159244A (zh) 包含减充血剂和皮质类固醇的鼻内组合物
CN105792828A (zh) 使用莫米松和奥洛他定的组合治疗过敏性鼻炎
KR20150011807A (ko) 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물
JP2014501779A (ja) ベポタスチン組成物
US9023815B2 (en) Method for treating rhinitis and sinusitis by rhamnolipids
CN102905689A (zh) 包含低剂量纳曲酮的液体鼻喷雾
CA2698135C (en) Osmolytes for treating allergic or viral respiratory diseases
JP2022535920A5 (cg-RX-API-DMAC7.html)
JP2024164155A (ja) 過剰摂取および報酬に基づく障害を処置するための、組成物、装置、および方法
US20200000751A1 (en) Carboxylic acids for treating/preventing nasal congestion
AU2012265231B2 (en) Nasal pharmaceutical formulation
JP2019505587A (ja) ベタメタゾン経口スプレー製剤及び運動失調の治療への使用方法
WO2020031148A1 (en) Pharmaceutical composition, medicinal product and method of treatment of bronchopulmonary obstructive diseases
ES2994461T3 (en) Method of diagnosis of adrenal insufficiency
WO2022076683A1 (en) Methods of treating coronaviral infection with obeticholic acid
JP6153193B2 (ja) アレルギー性疾患の予防または治療のための医薬組成物
RU2021121189A (ru) Композиции, устройства и способы для лечения расстройств передозировки и связанных с вознаграждением
CN111902138A (zh) 在乙酰胆碱酯酶抑制剂治疗失去反应的患者中对阿兹海默氏病的基于巴氯芬和阿坎酸的治疗